CB1 Receptor Antagonist Selonabant (ANEB‐001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial

Documenti analoghi

• TMS and EEG Pharmacodynamic Effects of a Selective Sphingosine‐1‐Phosphate Subtype 1 Receptor Agonist on Cortical Excitability in Healthy Subjects
  di: Catherine M. K. E. de Cuba, et al.
  Pubblicazione: (2024)
• Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial
  di: Andriy A. Gorbenko, et al.
  Pubblicazione: (2025)
• Ecopipam, a Dopamine D1 Receptor Antagonist: Pharmacokinetics, Mass Balance, and Metabolism in Healthy Volunteers
  di: Virginia D. Schmith, et al.
  Pubblicazione: (2026)
• Transcranial Magnetic Stimulation as a Translational Biomarker in Early‐Phase Anti‐Seizure Medication Development: A Randomized, Double‐Blind, Placebo‐Controlled Study in Generalized Epilepsy
  di: Catherine M. E. de Cuba, et al.
  Pubblicazione: (2026)
• On the use of open‐label studies for the evaluation of cannabis‐based products for the treatment of long COVID
  di: Andriy A. Gorbenko, et al.
  Pubblicazione: (2024)